2004
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: 1337-1342. PMID: 15275718, DOI: 10.1016/j.ijrobp.2004.02.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibiotics, AntineoplasticBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicConfidence IntervalsDoxorubicinDrug Resistance, NeoplasmFemaleHumansLymphatic MetastasisMastectomy, RadicalNeoadjuvant TherapyNeoplasm ProteinsNeoplasm Recurrence, LocalRadiation ToleranceReceptor, ErbB-2Receptors, EstrogenRegression AnalysisRetrospective StudiesConceptsHER2/neu-positive diseaseHER2/neu-positive tumorsLocoregional recurrenceHER2/neuNeoadjuvant doxorubicinHER2/neu-negative diseaseHER2/neu-negative tumorsEstrogen receptor-negative diseaseHER2/neu positivityHER2/neu overexpressionChest wall boostNeu-negative tumorsOverall LRR ratePositive lymph nodesReceptor-negative diseaseCox regression analysisEstrogen receptor statusLRR rateSupraclavicular diseaseHazard ratioLymph nodesReceptor statusPostmastectomy radiotherapyPreclinical dataNeu overexpressionTargeted Therapy in Breast Cancer The HER-2/neu Gene and Protein
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein. Molecular & Cellular Proteomics 2004, 3: 379-398. PMID: 14762215, DOI: 10.1074/mcp.r400001-mcp200.Peer-Reviewed Original ResearchConceptsBreast cancerNeu statusHormonal therapyAdvanced metastatic breast cancerHER-2/neu oncogeneHER-2/neu statusNew hormonal therapiesSerum-based testingMale breast cancerMetastatic breast cancerBreast cancer specimensClinical breast cancer specimensNeu gene amplificationEpidermal growth factor receptorTransmembrane tyrosine kinase receptorPrediction of responseGrowth factor receptorTyrosine kinase receptorsTrastuzumab therapyDuctal carcinomaNeu overexpressionHER-2Targeted therapyTumor cytosolsDisease outcome
2003
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist 2003, 8: 307-325. PMID: 12897328, DOI: 10.1634/theoncologist.8-4-307.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkers, TumorBreast NeoplasmsBreast Neoplasms, MaleCombined Modality TherapyEducation, Medical, ContinuingFemaleGene Expression Regulation, NeoplasticGenes, erbB-2Genetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedNeoplasm StagingPrognosisRisk AssessmentSensitivity and SpecificitySurvival AnalysisTrastuzumabTreatment OutcomeConceptsBreast cancerHER-2/neu statusHER-2/neu oncogeneNeu geneNew hormonal therapiesSerum-based testingMale breast cancerHER-2/neu geneTarget of therapyNeu gene amplificationEpidermal growth factor receptorTransmembrane tyrosine kinase receptorPrediction of responseGrowth factor receptorHormonal therapyTyrosine kinase receptorsTrastuzumab therapyDuctal carcinomaNeu overexpressionHER-2Disease outcomeTumor cytosolsTherapy responseNeu statusNeu testing